Lit Matters 3: Corticosteroid Therapy for Pneumonia

Severe community-acquired pneumonia is an inflammatory lung injury syndrome with high risk of respiratory failure, vasopressor use, and death. Early hydrocortisone in ICU-level CAP appears to improve patient-oriented outcomes, including 28-day mortality, while the bedside definition of “severe” matters more than ever.

Hydrocortisone for Severe CAP

• Inflammatory disease framing: Severe CAP is not just infection; the pulmonary and systemic inflammatory cascade drives hypoxemia, sepsis, organ dysfunction, and the excess mortality seen in ventilated patients.
• Target population signal: The benefit signal applies to ICU-level severe community-acquired pneumonia, defined by respiratory support needs or a high Pneumonia Severity Index rather than routine ward admissions.
• Mortality benefit: Early IV hydrocortisone lowered 28-day mortality from 11.9% to 6.2%, a patient-centered effect size that makes steroids hard to ignore in the right severe CAP patient.
• Airway escalation reduction: Among patients not ventilated at baseline, hydrocortisone reduced endotracheal intubation from 29.5% to 18.0%, suggesting fewer patients progressed to invasive respiratory support.
• Shock prevention signal: Hydrocortisone also reduced new vasopressor initiation from 25.0% to 15.3%, reinforcing the idea that steroids may blunt progression to hemodynamic collapse.
• Practical severity thresholds: The key bedside question is which pneumonia patients are severe enough to merit steroids, because the trial used specific respiratory and severity criteria rather than a vague gestalt. We walk through those inclusion signals in the episode.